Sunshine Biopharma Stock Analysis
| SBFM Stock | USD 2.10 0.18 7.89% |
Sunshine Biopharma is undervalued with Real Value of 76.66 and Target Price of 300.0. The main objective of Sunshine Biopharma stock analysis is to determine its intrinsic value, which is an estimate of what Sunshine Biopharma is worth, separate from its market price. There are two main types of Sunshine Biopharma's stock analysis: fundamental analysis and technical analysis.
The Sunshine Biopharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Sunshine Biopharma is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Sunshine Stock trading window is adjusted to America/New York timezone.
Sunshine |
Sunshine Stock Analysis Notes
The company has price-to-book ratio of 0.25. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sunshine Biopharma recorded a loss per share of 127.9. The entity last dividend was issued on the 6th of April 2020. The firm had 1:20 split on the 8th of August 2024. Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada. Sunshine Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. To find out more about Sunshine Biopharma contact Steve Slilaty at 954-515-0810 or learn more at https://sunshinebiopharma.com.Sunshine Biopharma Investment Alerts
| Sunshine Biopharma generated a negative expected return over the last 90 days | |
| Sunshine Biopharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 24.09 M. Net Loss for the year was (4.51 M) with profit before overhead, payroll, taxes, and interest of 10.14 M. | |
| Sunshine Biopharma currently holds about 41.74 M in cash with (8.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sunshine Biopharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Camille Sebaaly of 129468927 shares of Sunshine Biopharma subject to Rule 16b-3 |
Sunshine Biopharma Upcoming and Recent Events
| 2nd of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Sunshine Largest EPS Surprises
Earnings surprises can significantly impact Sunshine Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-13 | 2023-09-30 | -0.06 | -0.04 | 0.02 | 33 | ||
2023-08-14 | 2023-06-30 | -0.08 | -0.02 | 0.06 | 75 | ||
2024-05-20 | 2024-03-31 | -1.04 | -2.0 | -0.96 | 92 |
Sunshine Biopharma Environmental, Social, and Governance (ESG) Scores
Sunshine Biopharma's ESG score is a quantitative measure that evaluates Sunshine Biopharma's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Sunshine Biopharma's operations that may have significant financial implications and affect Sunshine Biopharma's stock price as well as guide investors towards more socially responsible investments.
Sunshine Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Main Street Group Ltd | 2024-09-30 | 0.0 | Nordwand Advisors Llc | 2024-12-31 | 0.0 | Connective Capital Management Llc | 2024-12-31 | 11.3 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 7.6 K | Ubs Group Ag | 2024-12-31 | 868 | Sbi Securities Co Ltd | 2024-12-31 | 709 | Bank Of America Corp | 2024-12-31 | 5.0 | Northwestern Mutual Wealth Management Co | 2024-12-31 | 4.0 | Td Waterhouse Canada Inc | 2024-12-31 | 1.0 | Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 1.0 | Rise Advisors, Llc | 2024-12-31 | 1.0 |
Sunshine Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.18 M.Sunshine Profitablity
The company has Profit Margin (PM) of (0.13) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.13.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.16) | |
| Return On Capital Employed | (0.20) | (0.19) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.24) | (0.23) |
Management Efficiency
Sunshine Biopharma has return on total asset (ROA) of (0.1075) % which means that it has lost $0.1075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1798) %, meaning that it created substantial loss on money invested by shareholders. Sunshine Biopharma's management efficiency ratios could be used to measure how well Sunshine Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of March 2025, Return On Tangible Assets is likely to grow to -0.16. In addition to that, Return On Capital Employed is likely to grow to -0.19. At this time, Sunshine Biopharma's Intangible Assets are very stable compared to the past year. As of the 24th of March 2025, Fixed Asset Turnover is likely to grow to 22.48, though Return On Tangible Assets are likely to grow to (0.16).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.6 K | 1.6 K | |
| Tangible Book Value Per Share | 1.5 K | 1.5 K | |
| Enterprise Value Over EBITDA | 2.12 | 2.23 | |
| Price Book Value Ratio | 0.36 | 0.34 | |
| Enterprise Value Multiple | 2.12 | 2.23 | |
| Price Fair Value | 0.36 | 0.34 |
The strategic decisions made by Sunshine Biopharma management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Technical Drivers
As of the 24th of March, Sunshine Biopharma has the Risk Adjusted Performance of (0.03), coefficient of variation of (2,361), and Variance of 19.46. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sunshine Biopharma, as well as the relationship between them. Please validate Sunshine Biopharma market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Sunshine Biopharma is priced more or less accurately, providing market reflects its prevalent price of 2.1 per share. Please also confirm Sunshine Biopharma jensen alpha, which is currently at (0.07) to double-check the company can sustain itself at a future point.Sunshine Biopharma Price Movement Analysis
The output start index for this execution was four with a total number of output elements of fifty-seven. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Sunshine Biopharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Sunshine Biopharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Sunshine Biopharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sunshine Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sunshine Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sunshine Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sunshine Biopharma Outstanding Bonds
Sunshine Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sunshine Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sunshine bonds can be classified according to their maturity, which is the date when Sunshine Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Sunshine Biopharma Predictive Daily Indicators
Sunshine Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sunshine Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Sunshine Biopharma Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
F3 | 21st of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 15th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 6th of January 2025 Other Reports | ViewVerify | |
8K | 10th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 12th of November 2024 Other Reports | ViewVerify | |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Sunshine Biopharma Forecast Models
Sunshine Biopharma's time-series forecasting models are one of many Sunshine Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Sunshine Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Sunshine Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Sunshine Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Sunshine shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Sunshine Biopharma. By using and applying Sunshine Stock analysis, traders can create a robust methodology for identifying Sunshine entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.15) | (0.16) | |
| Operating Profit Margin | (0.18) | (0.19) | |
| Net Loss | (0.17) | (0.18) | |
| Gross Profit Margin | 0.31 | 0.33 |
Current Sunshine Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Sunshine analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Sunshine analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 300.0 | Strong Buy | 1 | Odds |
Most Sunshine analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Sunshine stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Sunshine Biopharma, talking to its executives and customers, or listening to Sunshine conference calls.
Sunshine Stock Analysis Indicators
Sunshine Biopharma stock analysis indicators help investors evaluate how Sunshine Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Sunshine Biopharma shares will generate the highest return on investment. By understating and applying Sunshine Biopharma stock analysis, traders can identify Sunshine Biopharma position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 21.8 M | |
| Common Stock Shares Outstanding | 12.2 K | |
| Total Stockholder Equity | 21.2 M | |
| Tax Provision | 408.2 K | |
| Property Plant And Equipment Net | 1 M | |
| Cash And Short Term Investments | 16.3 M | |
| Cash | 16.3 M | |
| Accounts Payable | 2.6 M | |
| Net Debt | -15.6 M | |
| 50 Day M A | 2.516 | |
| Total Current Liabilities | 5.6 M | |
| Other Operating Expenses | 28.9 M | |
| Non Current Assets Total | 2.5 M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share | Quarterly Revenue Growth 0.416 | Return On Assets | Return On Equity |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.